Oric Pharmaceuticals Showcases Enozertinib Data at ESMO Asia Congress 2025
Oric Pharmaceuticals Inc. presented data from a Phase 1b trial of enozertinib at the ESMO Asia Congress 2025, focusing on EGFR atypical and exon 20 mutant NSCLC. The event included a conference call and webcast to discuss findings with the investment community. The news was originally published by Oric via GlobeNewswire.
Oric Pharmaceuticals Inc. announced two late-breaking oral presentations at the ESMO Asia Congress 2025, held from December 5-7, 2025, in Singapore. The presentations highlighted data from a Phase 1b trial of enozertinib (ORIC-114) in patients with EGFR atypical and EGFR exon 20 mutant non-small cell lung cancer (NSCLC). In conjunction with the congress, Oric hosted a conference call and webcast on December 6, 2025, to discuss the findings and engage with the investment community. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oric Pharmaceuticals Inc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9595837-en) on December 03, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
